cotadutide

Indications

• experimental drug for the treatment of type 2 diabetes mellitus

Dosage

• once daily SQ injection

Notes

• AstraZeneca has discontinued development of cotadutide in April 2023.
• the discontinuation was partly based on desire to focus on weekly administration rather than daily injections

More general terms

• GLP-1 receptor agonist